ZTS:NYE-Zoetis Inc. Class A

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 91.81

Change

+1.73 (+1.92)%

Market Cap

USD 44.24B

Volume

2.34M

Average Target Price

USD 94.20 (2.60%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Zoetis Inc discovers, develops, manufactures & commercializes animal health medicines & vaccines for livestock & companion animals. Its products include anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-10-16 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

+2.61 (+1.95%)

USD 366.36B
PFE Pfizer Inc.

+0.81 (+1.88%)

USD 257.52B
NVS Novartis AG

+2.57 (+3.09%)

USD 199.02B
MRK Merck & Company Inc. (new)

+1.76 (+2.53%)

USD 189.41B
ABBV AbbVie Inc.

+2.73 (+3.06%)

USD 139.18B
LLY Eli Lilly and Company

+0.41 (+0.37%)

USD 119.24B
SNY Sanofi American Depositary Sha..

+0.92 (+2.12%)

USD 111.03B
AZN Astrazeneca PLC

+1.61 (+4.30%)

USD 99.01B
GSK GlaxoSmithKline PLC

+0.92 (+2.37%)

USD 98.71B
BMY Bristol-Myers Squibb Company

+0.22 (+0.38%)

USD 94.37B

ETFs Containing ZTS

DXG:CA Dynamic iShares Active Gl.. 9.58 % 0.91 %

+0.55 (+1.93%)

CAD 0.17B
DXU:CA Dynamic iShares Active U... 9.26 % 0.89 %

+0.54 (+1.95%)

CAD 0.10B
MOO VanEck Vectors Agribusine.. 8.06 % 0.54 %

+1.39 (+2.20%)

USD 0.82B
IHE iShares U.S. Pharmaceutic.. 4.53 % 0.43 %

+4.40 (+2.79%)

USD 0.45B
XPH SPDR S&P Pharmaceuticals 4.41 % 0.35 %

+1.18 (+2.65%)

USD 0.36B
FTXH First Trust Nasdaq Pharma.. 4.09 % 0.60 %

+0.32 (+1.41%)

USD 3.41M
QGRO American Century STOXX U... 3.07 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.44% 95% A 94% A
Dividend Return 0.52% 9% F 8% F
Total Return 27.97% 90% A- 94% A
Trailing 12 Months  
Capital Gain 39.72% 95% A 94% A
Dividend Return 0.74% 17% F 9% F
Total Return 40.46% 95% A 94% A
Trailing 5 Years  
Capital Gain 179.14% 100% A+ 96% A
Dividend Return 5.66% 27% F 16% F
Total Return 184.81% 100% A+ 96% A
Average Annual (5 Year Horizon)  
Capital Gain 27.56% 100% A+ 95% A
Dividend Return 28.41% 100% A+ 95% A
Total Return 0.85% 27% F 17% F
Risk Return Profile  
Volatility (Standard Deviation) 19.13% 55% F 37% F
Risk Adjusted Return 148.53% 100% A+ 94% A
Market Capitalization 24.45B 52% F 96% A

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 40.27 39% F 15% F
Price/Book Ratio 22.67 9% F 3% F
Price / Cash Flow Ratio 6.61 5% F 16% F
Price/Free Cash Flow Ratio 30.91 17% F 18% F
Management Effectiveness  
Return on Equity 58.00% 91% A- 95% A
Return on Invested Capital 27.91% 91% A- 91% A-
Return on Assets 12.68% 91% A- 92% A-
Debt to Equity Ratio 268.00% 14% F 11% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

ZTS:NYE-Zoetis Inc. Class A

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 91.81

Change

+1.73 (+1.92)%

Market Cap

USD 44.24B

Volume

2.34M

Average Target Price

USD 94.20 (2.60%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-10-16